BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270205
DTSTAMP:20261016T064248Z
CREATED:20261016T064248Z
LAST-MODIFIED:20261016T064248Z
UID:44564-1801526400-1801785599@www.pharmajournalist.com
SUMMARY:2nd Structure-Based Drug Design Summit San Diego
DESCRIPTION:2nd Structure-Based Drug Design Summit San Diego: Advancing Structural Biology\, AI & Emerging Modalities for Next-Generation Drug Discovery \nReturning on February 2-4\, 2027\, the only west coast structural biology event is bringing together structural biologists\, computational chemists\, medicinal chemists\, and drug discovery leaders to explore how cutting-edge structural biology and AI-enabled technologies are transforming modern drug development. \nAs discovery teams face increasing pressure to de-risk pipelines\, tackle hard-to-drug targets\, and accelerate candidate progression\, this summit provides a unique forum to share practical strategies and real-world success stories from across the biopharma industry. \nOver three days of workshops\, presentations\, panel discussions\, and networking\, attendees will gain actionable insights into the integration of AI-driven structure prediction\, de novo protein design\, cryo-electron microscopy (cryo-EM)\, X-ray crystallography\, NMR\, HDX\, SAXS\, and other structural biology techniques. The event focuses on translating high-resolution structural insights into better decision-making\, faster candidate optimization\, and more efficient drug discovery workflows. \nView the full event breakdown here: https://ter.li/3qp8peig \nKey discussion topics include resolving conformational dynamics and cryptic binding pockets\, scaling cryo-EM through automation\, integrating computational and experimental approaches\, advancing predictive modeling\, and applying structure-based drug design (SBDD) to emerging therapeutic modalities such as molecular glues\, PROTACs\, biologics\, peptides\, and protein degradation strategies. \nThe summit features expert speakers and case studies from leading organizations including Pfizer\, Eli Lilly\, Amgen\, Calico Life Sciences\, Denali Therapeutics\, Vilya Therapeutics\, Deep Apple Therapeutics\, Degron Therapeutics\, and many more\, offering attendees the opportunity to learn directly from those at the forefront of structure-guided drug discovery. \nWhether you are looking to improve structure-guided medicinal chemistry\, enhance protein engineering capabilities\, leverage AI more effectively\, or unlock insights into complex biological targets\, the Structure-Based Drug Design Summit San Diego provides an unparalleled opportunity to connect with industry peers\, benchmark approaches\, and discover the latest innovations shaping the future of drug discovery. \nRegister & save today: https://ter.li/o7vi99fl
URL:https://www.pharmajournalist.com/event/2nd-structure-based-drug-design-summit-san-diego/
LOCATION:The Westgate Hotel\, 1055 2nd Ave\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270205
DTSTAMP:20261103T120203Z
CREATED:20261103T120133Z
LAST-MODIFIED:20261103T120203Z
UID:44672-1801526400-1801785599@www.pharmajournalist.com
SUMMARY:LEAP HR Life Sciences Europe
DESCRIPTION:Europe’s life sciences sector is navigating a period of unprecedented change. Funding constraints\, organisational restructuring\, evolving workforce expectations\, and uncertainty around AI’s long-term impact are forcing HR leaders to rethink how they attract\, retain\, develop\, and engage talent. \nReturning for its 9th year\, LEAP HR: Life Sciences Europe is the region’s only industry-specific forum bringing together senior HR leaders from organisations at every stage of growth. With attendees ranging from emerging biotechs preparing for commercialisation\, through to global enterprises managing complex transformations\, this is your unique opportunity to benchmark strategies\, exchange candid lessons learned\, and discover how peers are tackling the talent challenges unique to life sciences. \nThrough interactive discussions\, benchmarking opportunities\, and practical case studies\, gain direct access to fresh perspectives and proven strategies from peers facing similar challenges. You’ll leave this event with not only actionable ideas for workforce planning\, organisational design\, and AI adoption\, but also the trusted connections and ongoing support network needed to accelerate implementation and drive lasting impact within your organisation. \nTo know more visit: https://ter.li/ux78t040
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-europe-2027/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270224
DTSTAMP:20261106T112904Z
CREATED:20261106T112904Z
LAST-MODIFIED:20261106T112904Z
UID:44719-1803254400-1803427199@www.pharmajournalist.com
SUMMARY:SmartLab Exchange Europe 2027
DESCRIPTION:SmartLab Exchange Europe 2027 is the invitation-only forum for senior laboratory\, digital transformation\, data and R&D leaders responsible for accelerating innovation and driving digital transformation across the life sciences and process industries. Bringing together decision-makers from pharmaceutical\, biotech\, FMCG\, food & beverage and chemicals organisations\, the event provides a unique platform to explore the technologies\, strategies and operating models shaping the future of scientific research and development. \nAs organisations seek to operationalise artificial intelligence and advanced digital technologies\, many continue to face challenges including fragmented data environments\, disconnected laboratory systems\, workforce adoption barriers and difficulties scaling AI beyond proof-of-concept projects. SmartLab Exchange Europe 2027 addresses these challenges by focusing on practical\, real-world approaches to achieving successful R&D transformation and delivering measurable business value from digital initiatives. \nThe 2027 programme explores key industry priorities including AI-ready data foundations\, trusted AI governance\, laboratory orchestration\, connected scientific ecosystems\, workforce transformation and the emergence of self-driving laboratories. Through a combination of peer-led case studies\, panel discussions\, think tanks\, interactive roundtables and one-to-one meetings\, attendees will gain actionable insights from organisations successfully implementing AI\, automation and digital innovation across laboratory and R&D environments. \nAttendees will have the opportunity to benchmark their strategies against industry peers\, discover how leading organisations are building scalable AI capabilities\, and explore approaches to improving data quality\, interoperability and digital adoption across the laboratory landscape. The event also examines how organisations can create trusted foundations for AI\, connect previously siloed systems and transform laboratory operations to support faster\, more informed scientific decision-making. \nThe event features senior leaders from organisations including AstraZeneca\, Novartis\, Johnson & Johnson\, Kenvue and Henkel\, alongside an extensive faculty of laboratory\, digital and R&D transformation experts. Designed for leaders shaping the future of laboratory operations and scientific innovation\, SmartLab Exchange Europe 2027 offers a valuable opportunity to exchange best practices\, explore emerging technologies and build the partnerships needed to accelerate product development and unlock the full potential of AI-powered R&D. \nTo know more visit: https://bit.ly/4BHlPdJ
URL:https://www.pharmajournalist.com/event/smartlab-exchange-europe-2027/
LOCATION:Leonardo Royal Hotel Amsterdam\, Paul van Vlissingenstraat 24\, Amsterdam\, 1096 BK\, Netherlands
ORGANIZER;CN="IQPC Exchange":MAILTO:enquire@iqpcexchange.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270226
DTSTAMP:20261028T115729Z
CREATED:20261028T115729Z
LAST-MODIFIED:20261028T115729Z
UID:44627-1803340800-1803599999@www.pharmajournalist.com
SUMMARY:3rd Annual TRP Target Selection & Drug Design Summit
DESCRIPTION:The 3rd Annual TRP Target Selection & Drug Design Summit is the industry-dedicated discovery and preclinical forum for advancing the next generation of targeted radiopharmaceutical therapies. Taking place in Boston from February 23-25\, 2027\, the summit will unite more than 100 experts from across discovery\, biology\, medicinal chemistry\, radiochemistry\, ADME/DMPK\, toxicology\, radiobiology\, dosimetry\, preclinical development\, translational science\, and business development. \nAs established targets such as PSMA become increasingly crowded\, the meeting will help radiopharmaceutical developers identify novel targets\, explore new disease settings\, and create differentiated candidates with stronger clinical potential. Attendees will examine how clinically validated targets from ADCs\, RDCs\, immuno-oncology\, and other targeted modalities can be assessed and translated into radioligand therapy programs. \nThe agenda will explore emerging targets across CAIX\, MSLN\, the brain\, extracellular matrix\, and leukocytes\, alongside the biological factors that determine suitability for radiopharmaceutical development. Discussions will also cover targeting moieties\, linkers\, chelators\, radionuclide selection\, biodistribution\, kinetic imaging\, total-body PET\, digital SPECT\, computational biology\, dosimetry\, organ-specific toxicity\, and preclinical safety strategy. \nTwo interactive pre-conference workshops will provide focused learning on using advanced imaging and computational biology to identify high-potential targets\, as well as mining clinical validation from other therapeutic modalities to accelerate target selection. Across the main conference\, presentations\, roundtables\, case studies\, and networking sessions will help attendees benchmark candidate design and determine the evidence required to advance programs confidently toward the clinic. \nWith contributions from experts representing Bayer\, AstraZeneca\, Molecular Partners\, Mariana Oncology\, Harvard Medical School\, United Theranostics\, Ratio Therapeutics\, Affibody\, and other leading organizations\, the summit offers a focused opportunity to improve target selection\, strengthen drug design\, and build safer\, more differentiated radiopharmaceutical pipelines. \nTo know more visit: https://ter.li/ugtcnsbo
URL:https://www.pharmajournalist.com/event/3rd-annual-trp-target-selection-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270224
DTEND;VALUE=DATE:20270226
DTSTAMP:20261110T132343Z
CREATED:20261110T132343Z
LAST-MODIFIED:20261110T132343Z
UID:44746-1803427200-1803599999@www.pharmajournalist.com
SUMMARY:5th Viral Vector Process Development & Manufacturing Summit
DESCRIPTION:The 5th Annual Viral Vector Process Development & Manufacturing Summit brings together leaders across CMC\, process development\, manufacturing\, MSAT\, operations\, and regulatory affairs to advance robust\, reliable\, and reproducible viral vector manufacturing platforms. As the industry shifts towards optimizing proven AAV and LVV platforms\, the summit focuses on overcoming the challenges of scalable manufacturing\, process consistency\, regulatory readiness\, and commercial success. \nThrough real-world case studies\, scientific presentations\, panel discussions\, and networking opportunities\, attendees will explore strategies to improve vector yield\, enhance empty/full capsid separation\, optimize transfection and purification processes\, reduce cost of goods\, and accelerate development timelines through platform-based manufacturing approaches. \nThe summit will showcase practical insights from leading biopharma and biotech organizations including Regeneron\, Sanofi\, Ultragenyx\, Legend Biotech\, Cabaletta Bio\, and Apertura Gene Therapy\, providing attendees with actionable strategies to strengthen manufacturing performance\, improve product quality\, and support successful clinical and commercial outcomes. \nJoin a community of viral vector experts dedicated to increasing productivity\, reducing manufacturing and CMC burden\, and building the scalable processes needed to deliver the next generation of cell and gene therapies. \nFind out more today and secure your complimentary ticket: https://ter.li/2pthcqqz
URL:https://www.pharmajournalist.com/event/5th-viral-vector-process-development-manufacturing-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR